Streetbeat News

Stock Prices

ARES

Ares Management (NYSE:ARES) has significantly outperformed the market over the past 5 years, delivering an average annual return of 39.89%. An initial investment of $100 in ARES 5 years ago would now be worth $537.33. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 9:30 pm

GRAL

ILMN

Illumina's Board has approved the spin-off of GRAIL, with 'when-issued' trading expected to start around June 12, 2024. GRAIL will list on Nasdaq as 'GRAL' and Illumina shareholders will receive 85.5% of GRAIL's common stock, while Illumina retains 14.5%.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 9:25 pm

ACB

CGC

CRON

OGI

SNDL

TLRY

VFF

The Canadian recreational cannabis market is experiencing a slowdown, with a mere 2% YoY growth in Q1 2024. However, some companies like Village Farms International, Organigram Holdings, and Cronos Group have shown significant sales growth, while others like Tilray Brands and Canopy Growth Corporation have faced declines.

Portfolio Pulse from Nicolás Jose Rodriguez

June 03, 2024 | 9:01 pm

EPRT

Essential Properties Realty Trust (EPRT) has announced an increase in its quarterly dividend by 1.8%, from $0.285 to $0.29 per share. The dividend will be payable on July 12, 2024, to stockholders of record as of June 28, 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 9:01 pm

BSX

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years with an average annual return of 14.9%, resulting in significant compounded growth. A $100 investment 15 years ago would be worth $802.34 today.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 9:00 pm

MOH

Molina Healthcare (NYSE:MOH) has significantly outperformed the market over the past 10 years, delivering an average annual return of 21.42%. A $1000 investment in MOH 10 years ago would be worth $7,044.94 today. The article highlights the impact of compounded returns on long-term investment growth.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 9:00 pm

FGEN

REGN

FibroGen Inc (NASDAQ:FGEN) shares surged in after-hours trading following the FDA's clearance of its Investigational New Drug (IND) for FG-3165 and a new clinical trial supply agreement with Regeneron Pharmaceuticals (NASDAQ:REGN). FG-3165 is a galectin-9 targeted monoclonal antibody for treating solid tumors. Phase 1 trials are set to begin in the second half of 2024.

Portfolio Pulse from Adam Eckert

June 03, 2024 | 8:48 pm

SHIP

Sphinx Investment has released a statement regarding its investment in Seanergy Maritime, addressing ongoing litigation and shareholder proposals. Sphinx criticizes Seanergy's recent media statements and press release, suggesting that the company is attempting to mislead shareholders about the actions of its CEO and Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:47 pm

TER

Whales have shown a bullish stance on Teradyne (NASDAQ:TER) with significant options activity. Analysts have set an average price target of $158.4, with recent upgrades from Goldman Sachs. The stock is currently trading at $141.02 with a slight increase of 0.06%.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 8:45 pm

NET

Deep-pocketed investors have shown a bearish sentiment towards Cloudflare (NYSE:NET), with significant options activity detected. The majority of the trades are puts, indicating a bearish outlook. Analysts have mixed ratings, with price targets ranging from $80 to $120.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 8:45 pm